Webinar
Updates in Breast Cancer: Antibody-Drug Conjugates and Cyclin-Dependent Kinase Inhibitors
Date: June 15, 2026 | 2:00 PM
Login to Watch this Webinar
To watch the live webinar, login to your account or register to gain access to our exclusive content.
ADCs and CDK4/6 inhibitors continue to reshape breast cancer treatment across multiple disease settings. As indications expand and treatment approaches evolve, oncology teams are increasingly focused on balancing efficacy, tolerability, and long-term patient management.
In this CE-accredited session, Siân Behrendt-McLeroy, PharmD, MS (Texas Oncology), reviews
- The evolving role of CDK4/6 inhibitors in HR-positive breast cancer, including practical strategies to optimize tolerability in the adjuvant setting
- The expanding use of trastuzumab deruxtecan and its impact on treatment decisions across HER2-positive breast cancer
- Emerging evidence supporting the efficacy and safety of ADCs in metastatic triple-negative breast cancer
- Practical approaches for identifying, monitoring, and managing clinically significant adverse events associated with ADCs and CDK4/6 inhibitors
1.0 CE credit hours are available for pharmacists and pharmacy technicians.
For additional information or login assistance, reach out to NCODA’s Jonathan Rivera.